<DOC>
	<DOCNO>NCT00752570</DOCNO>
	<brief_summary>This clinical trial compare efficacy safety combination AMG 386 FOLFIRI FOLFIRI alone second line treatment metastatic colorectal cancer .</brief_summary>
	<brief_title>A Phase 2 , Randomized , Double Blind , Placebo Controlled Study AMG 386 Combination With FOLFIRI Subjects With Previously Treated Metastatic Colorectal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Trebananib</mesh_term>
	<criteria>Histologically confirm adenocarcinoma colon rectum patient present metastatic disease One one prior chemotherapy regimen metastatic disease consist combination fluoropyrimidinebased chemotherapy oxaliplatinbased chemotherapy . Prior adjuvant chemotherapy use prior onset metastatic disease permit At least one uni dimensionally measurable lesion per modify RECIST criterion . All sit disease must evaluate &lt; = 28 day randomization Radiographically document disease progression per modify RECIST criterion either receive &lt; = 6 month last dose prior chemotherapy regimen metastatic disease ECOG performance status 0 1 Man woman &gt; = 18 year age Adequate end organ assessment laboratory study ( hematological chemistry ) Life expectancy &gt; = 3 month Exclude subject history prior malignancy , except : Malignancy treat curative intent know active disease present &gt; = 3 year enrollment felt low risk recurrence treat physician Adequately treat nonmelanomatous skin cancer lentigo maligna without evidence disease Adequately treat cervical carcinoma situ without evidence disease Prostatic intraepithelial neoplasia without evidence prostate cancer Prior irinotecan therapy Systemic chemotherapy , hormonal therapy , immunotherapy &lt; = 21 day prior randomization Experimental approve proteins/antibodies ( eg , bevacizumab ) &lt; = 30 day prior randomization Clinically significant cardiac disease within 12 month prior randomization , include myocardial infarction , unstable angina , grade 2 great peripheral vascular disease , cerebrovascular accident , transient ischemic attack , congestive heart failure , arrhythmia control outpatient medication , percutaneous transluminal coronary angioplasty/stent Known allergy hypersensitivity irinotecan , 5 FU ( know dihydropyrimidine dehydrogenase deficiency ) leucovorin Active inflammatory bowel disease bowel disease cause chronic diarrhea ( define &gt; = CTC grade 2 [ CTCAE version 3.0 ] )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>colon cancer</keyword>
</DOC>